Gyre Therapeutics (GYRE) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Powered by 
Analysis
Gyre Therapeutics (GYRE) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -34.20% |
| Mar 31, 2026 | -404.41% |
| Dec 31, 2025 | -147.73% |
| Sep 30, 2025 | 276.61% |
| Jun 30, 2025 | -175.76% |
| Mar 31, 2025 | 2,825.25% |
| Dec 31, 2024 | -108.81% |
| Sep 30, 2024 | -68.14% |
| Jun 30, 2024 | -53.16% |
| Mar 31, 2024 | 107.46% |
| Dec 31, 2023 | -2,640.39% |
| Sep 30, 2023 | 114.57% |
| Jun 30, 2023 | -17.42% |
| Mar 31, 2023 | 107.50% |
| Dec 31, 2022 | -512.41% |
| Sep 30, 2022 | -109.46% |
| Jun 30, 2022 | 455.20% |
| Mar 31, 2022 | 28.43% |
| Dec 31, 2021 | 19.53% |
| Sep 30, 2021 | -26.65% |